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A B S T R A C T
Chronic gonadotropin-releasing hormone agonist (GnRHa) treatment is effective for the medical suppression of
the hypothalamic-pituitary-gonadal axis in situations like central precocious puberty and gender dysphoria.
However, its administration during the peripubertal period could influence normal brain development and
function because GnRH receptors are expressed in brain regions that regulate emotions, cognition, motivation
and memory. This study used an ovine model to determine whether chronic peripubertal GnRHa-treatment
affected the developmental shift from preference of familiarity to novelty. Experimental groups included
Controls and GnRHa-treated rams. To differentiate between effects of altered GnRH signaling and those asso-
ciated with the loss of sex steroids, a group was also included that received testosterone replacement as well as
GnRHa (GnRHa+T). Preference for a novel versus familiar object was assessed during 5-min social isolation at
8, 28 and 46 weeks of age. Approach behavior was measured as interactions with and time spent near the
objects, whereas avoidance behavior was measured by time spent in the entrance zone and attempts to escape
the arena via the entry point. Emotional reactivity was measured by the number of vocalizations, escape at-
tempts and urinations. As Control and GnRHa-treated rams aged, their approach behaviors showed a shift from
preference for familiarity (8 weeks) to novelty (46 weeks). In contrast, relative to the Controls the GnRHa+T
rams exhibited more approach behaviors towards both objects, at 28 and 46 weeks of age and preferred fa-
miliarity at 46 weeks of age. Vocalisation rate was increased in GnRHa treated rams in late puberty (28 weeks)
compared to both Control and GnRHa+T rams but this effect was not seen in young adulthood (46 weeks).
These results suggest that the specific suppression of testosterone during a developmental window in late
puberty may reduce emotional reactivity and hamper learning a flexible adjustment to environmental change.
The results also suggest that disruption of either endogenous testosterone signalling or a synergistic action
between GnRH and testosterone signalling, may delay maturation of cognitive processes (e.g. information
processing) that affects the motivation of rams to approach and avoid objects.
1. Introduction
Gonadotropin-releasing hormone (GnRH) is, classically, thought of
as a decapeptide that is synthesized in specialized hypothalamic neu-
rons and transported via the hypophyseal portal vessels to the anterior
pituitary gland, where it stimulates the release of the gonadotropins,
luteinizing hormone (LH) and follicle stimulating hormone (FSH). As
such, its importance in the regulation of pituitary-gonadal function has
long been recognized. The presence of GnRH (types I and II) and GnRH
receptors in other tissues (Hsueh and Schaeffer, 1985; Skinner et al.,
2009), including brain regions that are not primarily involved in the
regulation of reproductive function and behavior (Jennes et al., 1997;
Wilson et al., 2006; Skinner et al., 2009; Schang et al., 2010), suggests
that GnRH may have additional non-reproductive roles. In this regard,
GnRH neurons extend to extra-hypothalamic brain regions such as the
limbic system, which is important for the regulation of emotions,
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behaviors, motivations and memory. GnRH receptors are also expressed
in such areas and GnRH has been shown to be able to stimulate extra-
pituitary, neuronal, LH production (Wilson et al., 2006).
Within human and veterinary medicine, GnRH agonists (GnRHa)
are used chronically to suppress activity within the hypothalamo-pi-
tuitary-gonadal axis (HPG). This is possible, as continuous activation of
GnRH receptors leads to G protein receptor uncoupling, followed by
internalization and recycling of receptors (Ferguson et al., 1996;
Armstrong et al., 2011) and subsequent desensitization to the ligand.
GnRHa-treatments are used in pediatric medicine to suppress pubertal
changes in sex steroid hormones, in the treatment of gender dysphoria,
central precocious puberty, idiopathic short stature, growth hormone
deficiency, congenital adrenal hyperplasia, severe hypothyroidism and
autism (Carel et al., 2009). While the physical and reproductive
changes associated with GnRHa induced pubertal arrest have been
described, additional effects such as changes in cognition, emotional
control and motivated behaviors are not well characterized. However, it
is imperative to investigate the effects of chronic GnRHa-treatment
during the peripubertal period, as this represents a critical window of
neuronal development, plasticity and programming (Berenbaum and
Beltz, 2011) and therefore, any effects on brain function and behavior
may be long lasting or even permanent.
Using an ovine model, we previously reported sex- and age-depen-
dent effects of chronic peripubertal GnRHa-treatment on aspects of
cognition, behavior and emotional reactivity (Wojniusz et al., 2011;
Evans et al., 2012; Robinson et al., 2014; Hough et al., 2017). The in-
terpretation of the results of these studies is complicated, as the out-
comes may be influenced by the different testing conditions (Robinson
et al., 2014) or associated with suppressed sex steroid concentrations.
Nevertheless, a pattern is emerging that suggests some effects are
mediated via chronic peripubertal GnRHa action on the cognitive
processes that influence motivation. The results of earlier ovine studies
indicate that chronic peripubertal GnRHa can result in alterations in
avoidance behavior towards a novel object (Robinson et al., 2014),
approach behavior towards a preferred food source (Wojniusz et al.,
2011), emotional reactivity during social separation (Evans et al.,
2012), and motivation to traverse a spatial maze to reunite with peers
(Hough et al., 2017).
Novelty preference behavior can provide valuable insights to cog-
nitive factors that influence motivation, as it reflects the outcome of
judging associated risks against possible reward under different test
conditions (Doyle et al., 2010; Ernst, 2014). In mammals, novelty
preference behavior is sexually differentiated, with females typically
exhibiting more negative emotions like fear/anxiety or avoidance to
novel objects/situations compared to males. Novelty/familiarity pre-
ferences change with age in both sexes. At puberty changes in behavior
that favors novelty and risk-taking become apparent, with a relative
disregard for potential negative consequences, particularly in males
(Spear, 2000; Ernst et al., 2009). It is likely that reproductive hormones
have a regulatory role in such reactions and, therefore, these may be
affected by blockade of the pubertal transition.
The aims of the present study were to 1) investigate the effects of
chronic peripubertal GnRHa-treatment on novelty preference behavior
as a measure of cognitive processes that influence motivation, and 2)
differentiate between the effects of chronically disrupted peripubertal
GnRH and gonadal steroid signaling in males before and after puberty.
2. Materials and methods
2.1. Animals and treatment
The research was conducted at the University of Glasgow Cochno
Farm and Research Centre (55° 55′N) in accordance with Home Office
Regulations (Project License: 60/4422). Animals were male Scottish
Mule Texel crosses born between 23 March and 12 April 2013 (the
mean age of animals on 30th March was 1 week). All animals came
from single sex litters, to control for any effects of differences in the
prenatal steroid environment associated with female siblings. Lambs
were maintained with their dams until weaned at approximately 21
weeks of age. All sheep were grazed on pasture, except during beha-
vioral trials, when indoor-housed sheep had ad libitum access to hay or
silage and other nutritional supplements according to standard man-
agement practices.
At birth, lambs were randomly assigned to one of three treatment
groups, with twins and triplets split across groups to minimize any
maternal effects. The groups were: 1) untreated Control rams (Control,
n=60); 2) chronic GnRHa-treated rams (GnRHa, n=55); and 3)
chronic GnRHa-treated rams that also received testosterone replace-
ment therapy (GnRHa+T, n=24) to tease apart treatment effects
associated with either GnRH or gonadal sex steroids. GnRHa-treatment
(subcutaneous implant of goserelin acetate, Zoladex3.6mg, kindly do-
nated by Astra Zeneca, Macclesfield, UK) commenced at 8 weeks of age
(pre-pubertal) and was administered every fourth week, until 1 year of
age. To mimic the endogenous testosterone concentrations expected in
the Controls, testosterone was replaced from 16 weeks of age until the
end of the experiment via 2-weekly intramuscular injection of testos-
terone cypionate (A6960-000, Steraloids, Newport, USA) dissolved in
vegetable oil as previously described (Wood et al., 1991). Based on the
testosterone profiles published by Robinson et al. (2014), testosterone
cypionate doses were: 16 weeks, 50mg; 18–24 weeks, 120mg; 26–30
weeks, 160mg; 32–46 weeks, 240mg; and 48 weeks, 136.4mg.
2.2. Testes size and circulating testosterone concentrations
Every 4 weeks, from 8 weeks of age, on the day of GnRHa and
testosterone cypionate administration, blood was collected, testes
measured (length and circumference of scrotum in cm) and body
weight (kg) recorded. Additional daily blood samples were collected
from 10 GnRHa+T animals for 14 consecutive days in October (28–30
weeks of age) to characterize circulating testosterone concentrations in
response to exogenous testosterone cypionate treatment (Supplemental
Fig. 1). Blood samples (3mL) were collected by jugular venipuncture
and placed in heparin-treated tubes. After centrifugation at 5000 g for
15min at 4 °C, plasma was harvested and stored at −20 °C.
Testosterone concentrations were quantified by RIA, as previously de-
scribed (Sheffield and O’Shaughnessy, 1989), following diethyl ether
extraction from 50 μL plasma. Assay sensitivity averaged 0.02 ng/mL,
and the intra- and inter-assay coefficients of variation were 8.1% and
5.9%, respectively. Assay of assay buffer/BSA supplemented with 1 ng/
mL testosterone cypionate indicated that it did not cross react and was
therefore undetectable with this RIA.
2.3. Assessment of novelty preference behavior
Novelty preference behavior was assessed over 2–4 days, at three
developmental ages: 8 weeks (pre-pubertal, prior to GnRHa and tes-
tosterone treatment), 28 weeks (post-pubertal and during the breeding
season) and 46 weeks (post-pubertal and during the non-breeding
season). At each age, animals from the three groups were assessed in a
random order (GnRHa+T animals were tested between 3–11 days post
testosterone cypionate treatment (Supplemental Fig. 1). The indoor test
arena (8.7 m×6m, Fig. 1) had concrete flooring and was bordered by
either a concrete-brick wall or fencing covered with black plastic
sheeting. A 1m diameter ‘inner zone’ and a 2m diameter ‘outer zone’
were marked on the floor surrounding the two test objects, to allow
assessment of proximity to, and interest in an object (i.e. approach
behavior). An ‘entrance zone’ was designated 0.5m from the border
with the gate. The remainder of the test arena floor area was designated
a ‘neutral zone’. The behavioral test arena was fitted with two high-
resolution day/night cameras (Cameras: KS-779VR, Eyeball 700 TV L,
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Vari-focal 2.8–12mm; DVR: Guardian 4 G, K-DVR-4 G1, 500GB HDD;
Digital Direct Security, Huntingdon, UK). To ensure familiarity with the
test arena and the familiar object (two stacked red drinks crates), all
animals had access to the test arena and the familiar object for ap-
proximately 24 h prior to the assessment. The novel objects were
chosen to be of similar size and material, but different in shape and
color from the familiar object. The novel object at 8 weeks of age was
an orange traffic cone, at 28 weeks of age, a triangular yellow ‘wet
floor’ sign, and at 46 weeks of age, a 5-gallon blue water bottle tied to a
grey dustbin. After assessment of each animal, objects were sprayed
with ethanol and wiped with paper towels to remove olfactory cues.
Any feces or urine were also removed from the floor of the test arena
and the area sprayed with ethanol. The placement of the novel and
familiar objects on the right or left side of the area were alternated
between each assessment.
For each assessment, one sheep was ushered through a gate into the
test arena by an experienced handler. The sheep was allowed to explore
the arena and its contents for 300 s, after which it was shepherded
through the same gate with which it had entered. During each assess-
ment, the time spent in the respective zones was quantified and the
number of physical explorations of the novel and familiar objects (e.g.
touching, licking, nudging, sniffing) recorded. Emotional reactivity was
assessed by counting the number of vocalizations, escape attempts and
urinations/defecations. An escape attempt was defined as a proactive
effort to move through, over or under the border of the test arena.
Revision of video footage was used to determine the time spent in each
zone within the test arena. Presence in a zone was defined from when
one foreleg was placed within that zone.
2.4. Statistical analyses
As statistical analysis indicated that body weight influenced testes
size, the measure of testes size used in the analyses was calculated as
(testes length× circumference)/body weight (cm2/kg). Time spent
near an object was defined as the time an animal was within the inner
and outer zones surrounding each object. Novelty preference was de-
fined as the percentage of time spent near the novel object, relative to
the total time spent near both objects, and the number of exploratory
interactions with the novel object relative to the total number of object
interactions. Statistical analyses were performed with R software
(Version 3.2.5, © 2015 The R Foundation for Statistical Computing
Platform) using the RStudio interface (Version 1.0.136, © 2009–2015
RStudio Inc.). All variables were analyzed with two-factorial ANOVA
(Treatment×Age) using linear mixed-effects models with repeated
measures (sheep identity specified as random factor) and the data dis-
tribution specified as Gaussian for continuous data (time spent in zones,
% object preference, plasma testosterone and testes size, all of which
were square root transformed for best fit based on the minimum Akaike
information criterion for model selection) or Poisson for count data
(number of interactions, urinations, escape attempts and vocalizations).
To differentiate between the effects of GnRH and testosterone, respec-
tively, two-tailed t-tests (or Wilcoxon signed-rank tests for non-para-
metric data) were used at each age (Control vs GnRHa, Control vs
GnRHa+T, GnRHa vs GnRHa+T). All values presented are the mean
and standard error of the mean of untransformed data. There were no
between group differences, for any variable, prior to the start of the
treatment at 8 weeks of age and, therefore, overall population means
are presented in tables and figures. For all statistical tests an alpha-level
of 0.05 was considered statistically significant and where alpha<0.09,
trends are reported.
3. Results
3.1. Testes size and circulating testosterone concentrations
In Control rams, plasma testosterone concentrations and testes size
increased from 12 weeks of age (Fig. 2) and reached a maximum be-
tween 26–36 weeks of age, after which both declined (Age P < 0.001).
After 8 weeks of age, testes size was similar in both GnRHa-treated
groups, but significantly (P < 0.001) lower compared to the Controls.
While mean circulating testosterone concentrations increased in all
groups, this increase was significantly delayed in both GnRHa-treated
groups compared to Controls (Treatment×Age P=0.004). Testos-
terone concentrations were significantly lower in GnRHa rams
(P < 0.05) between 20–32 weeks of age. It should be noted that values
in Fig. 2A for the GnRHa+T rams represent concentrations 14 days
after testosterone cypionate administration (Supplemental Fig. 1).
Fig. 1. Design of the novelty preference arena. Zones were marked with spray-
painted lines on the floor to assist in video analyses.
Fig. 2. Changes in plasma testosterone (A) and
testes size per body weight (B) of rams from
pre- to post-puberty in Control, chronic peri-
pubertal GnRHa-treated (GnRHa) and GnRHa-
treated with testosterone cypionate replace-
ment (GnRHa+T) rams. Values for
GnRHa+T animals represent concentrations
on day 14 after treatment with testosterone
cypionate (Supplemental Fig. 1).
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3.2. Age effects
3.2.1. Time allocation in test arena
At all ages, rams spent the most time in the neutral zone (Table 1).
Overall, rams spent more time in the neutral zone at 28 weeks of age
(55%), than at 8 (43%) and 46 (45%) weeks of age (Tables 1 and 2). At
8 weeks of age, rams spent more of the assessment time near both
objects (33%) and less time in the entrance zone (24%), but this pattern
was reversed at 28 (21% both objects, 24% entrance) and 46 (21% both
objects, 34% entrance) weeks of age (Tables 1 and 2).
The amount of time animals spent near the novel and familiar ob-
jects (Table 1) significantly decreased with age (Table 2). In each case,
the largest change was seen between 8 and 28 weeks of age, whereas
the amount of time spent near these objects was similar between 28 and
46 weeks of age. Of the time spent near the objects, at 8 weeks of age,
rams spent proportionately more time in the outer than in the inner
zone of the objects (Table 1; Familiar object, 54% outer : 46% inner;
Novel object, 56% outer : 44% inner). Interestingly, this pattern was
reversed at 28 (Familiar object, 44% outer: 56% inner; Novel object,
41% outer: 59% inner), but not at 46 weeks of age (Familiar object,
56% outer: 44% inner; Novel object, 50% outer: 50% inner). The per-
centage of total time spent with the novel, relative to familiar object,
did not change significantly (P=0.335) with age as the novelty
preferences across all animals assessed at 8, 28 and 46 weeks of age
were 46 ± 2.8, 47 ± 1.8, and 50 ± 1.6%, respectively.
3.2.2. Object explorations
The number of explorations of the familiar object decreased with
age (Tables 1 & 2), whereas it remained unchanged for the novel object
(Table 1 and 2). Consequently, as rams aged the total number of in-
teractions with the objects tended (Table 2) to decrease (Table 1), but
the percentage of interactions with the novel object (Fig. 3) increased
significantly from week 8 to weeks 28 and 46 (P < 0.05; 8 wk:
45 ± 2.7%, 28 wk: 52 ± 2.3%, 46 wk 51 ± 2.0%). There were no
statistically significant difference in these parameters between weeks
28 and 46.
3.2.3. Emotional reactivity
Overall, there was a significant decrease with age in the number of
vocalizations (P < 0.001) and urinations (P < 0.05) during the
testing period with the largest change seen between 8 and 28 weeks of
age (Table 3). With age, rams were significantly (P < 0.001) more
likely to make escape attempts (Table 3), with the largest increase seen
between 28 and 46 weeks of age.
Table 1
Summary of the results for the time (in sec) spent in each zone of the arena and number of interactions with the objects during the 300-second testing period.
Different superscript letters represent significant differences (P < 0.05) between treatment groups from t-tests at that age.
8 wks 28 wks 46 wks
All animals
n=80
Control n=42 GnRHa n=39 GnRHa+T
n=23
All animals
n=104
Control n=48 GnRHa n=43 GnRHa+T
n=21
All Animals
n=102
Zone times (sec)
Neutral 129.4 ± 6.1 171.0 ± 5.1 157.1 ± 5.4 166.3 ± 6.2 164.8 ± 3.2 132.2 ± 6.0 132.5 ± 6.3 145.0 ± 7.5 134.7 ± 3.8
Entrance 70.5 ± 4.5 71.7ab ± 5.5 79.0a± 5.7 58.9b ± 7.9 71.5 ± 3.6 107.4a± 6.3 105.4ab± 7.6 83.3b±8.8 102.1 ± 4.4
Both objects 100.1 ± 6.1 57.3a ± 3.5 64.9ab ± 4.2 74.0b ± 5.3 63.8 ± 2.5 60.4 ± 4.2 62.0 ± 4.2 71.7σ±4.8 63.1 ± 2.6
Familiar object 58.4 ± 5.1 31.1 ± 2.4 33.6 ± 3.0 40.0 ± 4.2 34.0 ± 1.8 28.2a ± 2.4 30.3a ± 2.5 43.1b±4.4 31.8 ± 1.7
Inner 26.6 ± 2.9 17.4 ± 1.9 18.0 ± 2.1 24.6 ± 3.2 19.2 ± 1.3 13.5a ± 1.8 12.4a ± 1.4 18.6b±2.6 14.0 ± 1.1
Outer 31.8 ± 2.7 13.7 ± 1.3 15.6 ± 1.6 15.4 ± 1.7 14.8 ± 0.9 14.7a ± 1.1 17.9a ± 1.6 24.5b±2.7 17.8 ± 1.0
Novel object 41.7 ± 3.4 26.2 ± 2.1 31.3 ± 3.5 34.0σ±3.1 29.8 ± 1.7 32.2 ± 2.9 31.8 ± 2.5 28.6 ± 3.3 31.4 ± 1.7
Inner 18.2 ± 1.8 15.6 ± 1.7 19.4 ± 2.7 18.8 ± 2.2 17.7 ± 1.3 16.5 ± 2.2 15.5 ± 1.5 15.1 ± 2.3 15.8 ± 1.2
Outer 23.5 ± 2.2 10.6a ± 1.0 11.8a ± 1.6 15.2b± 1.7 12.1 ± 0.8 15.8 ± 1.3 16.3 ± 1.6 13.5 ± 1.7 15.5 ± 0.9
Interactions (no.) 6.5 ± 0.4 5.2b ± 0.3 5.3ab ± 0.4 6.4a,†± 0.5 5.5 ± 0.2 5.0 ± 0.3 5.2 ± 0.4 6.1σ± 0.6 5.3 ± 0.2
Familiar 3.6 ± 0.3 2.6ab ± 0.2 2.3b ± 0.3 3.3a,σ± 0.4 2.8 ± 0.2 2.3a± 0.2 2.5ab,†± 0.2 3.4b± 0.4 2.7 ± 0.1
Novel 2.9 ± 0.2 2.6 ± 0.2 2.9 ± 0.3 3.1 ± 0.4 2.6 ± 0.2 2.7 ± 0.2 2.7 ± 0.2 2.7 ± 0.4 2.6 ± 0.2
σ Control vs GnRHa+T P = 0.05-0.1.
† GnRHa vs GnRHa+T P = 0.05-0.1.
Table 2
Summary of P-values obtained from a two-factorial ANOVA (Treatment×Age)
to assess the effects of treatment and age on the time spent in each zone of the
arena and interactions with the objects during the 300-second test period.
***P < 0.001, *P < 0.05, ‘P < 0.1.
Arena area Treatment Age Treatment x Age
Zone times (sec)
Neutral 0.986 <0.001*** 0.116
Entrance 0.082‘ < 0.001*** 0.282
Both objects 0.204 <0.001*** 0.277
Familiar object 0.082‘ < 0.001*** 0.634
Inner 0.105 <0.001*** 0.865
Outer 0.212 <0.001*** 0.209
Novel object 0.913 0.008** 0.094‘
Inner 0.841 0.673 0.386
Outer 0.217 <0.001*** 0.045*
Interactions (no)
Total 0.218 0.082‘ 0.812
Familiar 0.027* <0.001*** 0.596
Novel 0.875 0.633 0.513
Fig. 3. Percentage of interactions with the familiar and novel objects during the
300-second testing period at 8, 28 and 46 weeks of age. *P < 0.05,
**P < 0.01.
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3.3. Treatment effects
3.3.1. Time spent in specific zones in the test arena
While there were no overall effects of treatment (Table 2) on time
spent in each zone within the test arena (Table 1), there was a sig-
nificant treatment by age interaction with regard to the time spent in
the outer zone of the novel object. Specifically, the GnRHa+T group
spent more time in this zone than the Control and GnRHa groups at 28,
but not 46 weeks of age (Table 1).
Comparisons of treatment groups at 28 and 46 weeks of age in-
dicated significant differences with regard to the time spent in different
zones and explorations of the objects (Table 1). The GnRHa+T rams
spent significantly less time in the entrance zone than the GnRHa rams
at 28 weeks of age and the Control rams at 46 weeks of age (Table 1).
The GnRHa+T group spent a significantly greater amount of time near
both objects than the Control group at 28 weeks of age (P < 0.05) and
a similar trend (P=0.076) at 46 weeks of age. At 28 weeks of age the
GnRHa+T rams spent more (P < 0.05) time in the outer zone of the
novel object than the other groups, which was also reflected by a trend
(P=0.053) for GnRHa+T rams to spend more time near the novel
object. However, at 46 weeks of age the GnRHa+T rams spent
(P < 0.01) more time near the familiar object (Table 1) compared to
the other groups. This effect was also noted in the time spent in the
inner and outer zones of the familiar object (P < 0.05, Table 1). The
percentage of time spent near the novel, relative to the familiar, object
did not differ at 28 weeks of age (Control 45 ± 2.5%, GnRHa
47 ± 3.3%, GnRHa+T 48 ± 4.0%), but at 46 weeks of age the
GnRHa+T group had lower (P < 0.01) novelty preferences
(39± 4.2%) than the Control (53±2.4%) and GnRHa (52 ± 2.4%)
groups (Treatment P=0.226, Treatment×Age P=0.274).
3.3.2. Object explorations
The GnRHa+T rams explored (Table 2) the familiar object more
than the Control and GnRHa rams (Table 1). The number of exploratory
interactions the GnRHa+T group had with the familiar object was
similar at all ages (Table 1). Thus, there was a significant treatment
effect (Treatment P=0.021, Treatment × Age P=0.333) on object
interaction preference, whereby at 46 weeks of age GnRHa+T rams
displayed a greater preference (Fig. 3) for exploratory interactions with
the familiar object whereas the GnRHa and Control rams preferred in-
teractions with the novel object.
3.3.3. Emotional reactivity
Effects of treatment were limited to vocalizations at 28 weeks of age
(Treatment×Age P < 0.001, Treatment P=0.267). GnRHa rams
vocalized more than GnRHa+T rams at 28 weeks of age and tended
(P=0.058) to vocalize more than Control rams (Table 3). There were
no significant differences between treatment groups at 46 weeks of age.
4. Discussion
Novelty preference behavior provides valuable insight into cogni-
tive processes that influence motivation as an individual balances the
potential risk of the new, against the possible but unknown reward that
may arise as a result of exploring an unfamiliar object. These cognitive
processes can further be influenced by the conditions in which the novel
item is encountered and the emotional state of the subject (Doyle et al.,
2010; Ernst, 2014). Novelty preference in humans and animals is
sexually dimorphic and changes during puberty. The results of this
study show that chronic disruption of peripubertal GnRH signaling in
rams, without testosterone replacement, neither altered the pre- to post-
pubertal decline in approach behaviors towards familiar and novel
objects nor the increase in preference for novelty, but was associated
with increased vocalizations in late puberty (28 weeks of age). The
replacement of testosterone ameliorated GnRHa-mediated differences
in vocalization rates, but resulted in the disruption of age related
changes in approach behavior where this did not decline with age, as in
the other groups. These animals also showed a clear preference for fa-
miliarity in adulthood. As these animals received exogenous testos-
terone, the main physiological consequence of treatment was the dis-
ruption of GnRH signaling as opposed to both GnRH and testosterone
signaling. Therefore the results suggest that both peripubertal GnRH
and testosterone may modulate behavior and cognitive function during
normal peripubertal development.
4.1. Testes size and circulating testosterone concentrations
Increased testes size and circulating testosterone concentrations
after 14 weeks in Controls indicated that these animals had passed
through the pubertal transition. GnRHa suppressed reproductive de-
velopment, as in the GnRHa-treated groups changes in testis size were
minimal. Despite this, there was a delayed increase in mean testos-
terone concentrations in GnRHa-treated rams, relative to the Controls,
followed by a decrease after 34 weeks of age that would correspond
with the end of the breeding season in the Controls. This result is similar
to that reported for GnRHa-treated men where spermatogenesis i.e.
reproductive potential was suppressed although circulating testosterone
concentrations did not drop to hypogonadal levels (Bhasin et al., 1987).
In the current experiment, the smallest testes:body weight ratio was
seen in the GnRHa+T rams, which is consistent with other findings
(Heber and Swerdloff, 1981; Bhasin et al., 1987) that GnRHa and
exogenous testosterone act synergistically to inhibit gonadotropin se-
cretion and thus testes size. Testosterone concentrations in the Controls
declined towards the end of the experiment, which corresponds to the
non-breeding season, whereas exogenous testosterone administration in
the GnRHa+T rams was maintained. This discrepancy in circulating
androgen concentrations, along with the loss of biological patterns of
testosterone secretion in the GnRHa+T rams, may have exaggerated
some effects at 46 weeks of age within this experimental paradigm.
4.2. Developmental shift from familiarity to novelty preference
With age, a shift was observed in the preference of Control rams
from familiarity to novelty. A similar developmental transition towards
novelty preference is reported in humans, where it can be observed
from as early as 7 months of age (Shinskey and Munakata, 2010). This
shift towards novelty preference has been ascribed to developmental
changes in information-processing abilities regulated by the prefrontal
Table 3
Summary of results for the behavioral observations (number of events) during the novelty preference test. Superscript letters indicate results of t-tests with the same
letters representing non-significant differences between treatment groups at that age.
Observation 8 wks 28 wks 46 wks
All Animals
n=77
Control n=44 GnRHa n=41 GnRHa+T
n=25
All Animals
n=110
Control n=50 GnRHa n=43 GnRHa+T
n=21
All Animals
n=114
Vocalizations 55.8 ± 2.2 18.7ab± 1.7 23.5a± 1.8 16.6b± 2.8 20.0 ± 1.2 9.7 ± 1.3 10.9 ± 1.7 12.3 ± 2.5 10.6 ± 1.0
Urination events 0.45 ± 0.08 0.32 ± 0.09 0.27 ± 0.07 0.32 ± 0.11 0.30 ± 0.05 0.26 ± 0.07 0.14 ± 0.06 0.19 ± 0.09 0.20 ± 0.04
Escape attempts 1.38 ± 0.29 2.73 ± 0.61 2.17 ± 0.66 1.36 ± 0.47 2.21 ± 0.36 8.02 ± 0.85 7.23 ± 0.97 6.33 ± 0.92 7.41 ± 0.55
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cortex (Fagan et al., 2007) and reduced novelty preferences during
infancy were associated with lower cognitive performance in adulthood
(Fagan et al., 2007).
Interestingly, the effects on post pubertal novelty preference dif-
fered between the GnRHa and GnRHa+T rams. Rams that received
both peripubertal GnRHa and testosterone replacement, had a lower
post pubertal novelty preference. This could suggest that a loss of GnRH
signaling is associated with disruption of the development of the neural
circuits that regulate novelty/familiarity interactions that might nega-
tively impact new learning and preference decision-making in adult-
hood. The same effect, however, was not seen in the rams in which both
GnRH and testosterone signaling were suppressed. The lack of an effect
in the GnRHa group could be explained if GnRHa-treatment modulated
functions that are GnRH and testosterone-sensitive (i.e. act synergisti-
cally) or if the effects in the GnRHa+T rams are the result of main-
tained high concentrations of exogenous testosterone in this group re-
lative to the Controls.
4.3. Object approach and avoidance behavior
While in the arena, the motivation of animals to approach objects
was assessed by the time spent near the objects, which decreased from 8
to 28 weeks of age in Controls. This contrasts with an age dependent
increase (between 28 to 46 weeks) in avoidance behavior, which for
this study was reflected by the time spent in the entrance zone and the
number of escape attempts, where animals expressed typical flight be-
haviors as they searched for their entry point and/or expressed a strong
desire to return to their social peers. It is of note that many animals and
humans share elements that regulate the functions of escape behaviors
which take precedence over all other activities including social beha-
vior, although some species or prey-predator differences may exist in
safety and defense strategies (Dixon, 1998). If not engaged with the
objects or expressing avoidance behaviors, it was possible for animals to
spend time in the neutral zone where they did not display strong mo-
tivation to either approach or avoid the objects/escape the test arena, in
the Controls this behavior was most pronounced at 28 weeks of age.
This developmental shift from pre-puberty to young adulthood whereby
approach behavior decreased, and avoidance behavior increased, is in
line with human studies where these changes are attributed to temporal
differences in the maturation of specific neural networks among the
amygdala, ventral striatum and prefrontal cortex (Ernst et al., 2009;
Ernst, 2014).
In the present study, the lack of an effect of GnRHa on the post-
pubertal increase in avoidance and decrease in approach behaviors was
similar to a previous study examining responses of male and female
GnRHa treated (peripubertal) sheep to a novel object (Robinson et al.,
2014). However, in the present study the replacement of testosterone
significantly decreased avoidance behaviors, particularly the time spent
in the entrance zone, and increased object approach behaviors. Thus,
the peripubertal co-treatment with GnRHa and exogenous testosterone
appears to have disrupted the maturational changes in cognitive pro-
cesses that affect motivation, namely increased approach versus
avoidance behavior towards objects in social isolation and/or decreased
drive to flock. This observation is consistent with a former study with
the same animals (Hough et al., 2017) where GnRHa+T rams ex-
hibited reduced motivation to complete a spatial task to reunite with
peers. In other studies, GnRHa-treated rams (no exogenous testos-
terone) also had reduced motivation to traverse a spatial maze
(Wojniusz et al., 2013; Nuruddin et al., 2013c), and were more likely to
engage in risk-taking behavior in a food-acquisition task (Wojniusz
et al., 2011). The latter studies are also supported by data that indicated
that peripubertal GnRHa-treatment is associated with an increase in
amygdalae volume at 48 weeks of age (Nuruddin et al., 2013a). Col-
lectively, these observations support our hypothesis that both peripu-
bertal GnRH and testosterone signaling can affect maturational changes
in selected cognitive processes that regulate motivation as a result of
brain plasticity during adolescence.
4.4. Emotional reactivity
The decrease in the number of vocalizations and urinations with age
in Control rams reflects the maturational change in emotional reactivity
reported previously (Wosjniusz, et al., 2011; Evans et al., 2012;
Robinson et al., 2014; Hough et al., 2017). In the current study, novelty
preference was assessed while animals were in social isolation. Due to
strong social grouping (Lyons et al., 1993), animals were probably
tested in a state of heightened anxiety. Previous studies have shown
that vocalization rates are markedly increased when sheep have no
physical or visual contact with their peers (Lyons et al., 1993). Emo-
tional state can result in judgement bias in sheep (Doyle et al., 2010)
and as such, we would hypothesize that, within this experimental de-
sign, avoidance (i.e. ‘flight’, Dixon, 1998) would be favored over ap-
proach with animals spending more time in the entrance or neutral
zones than close to objects.
As previously reported (Evans et al., 2012), vocalization rates were
increased at 28 weeks of age in isolated GnRHa rams, relative to Con-
trols, but this effect was lost with age. As this effect was not observed in
the GnRHa+T rams, transient effects could be due to the ability of
testosterone (endogenous in Controls or exogenous in GnRHa+T
rams) to drive an aspect of emotional maturation that normally occurs
early during the pubertal transition, but is not essential to reach ma-
turity. Such a change in emotional reactivity could be related to the
surges in emotional lability observed in humans at the advent of the
pubertal transition and occur in association with developmental
changes in the amygdala that continue into adulthood (Steinberg, 2008;
Ernst, 2014).
Girls with central precocious puberty, who receive chronic GnRHa-
treatment demonstrate increased emotional reactivity (Wojniusz et al.,
2016) but lower resting heart rates and unchanged cognitive or psy-
chosocial functioning. This suggests they process emotional stimuli
differently. Our ovine studies have reported that chronic peripubertal
GnRHa-treatment is associated with changes in amygdala volume in
adulthood (Nuruddin et al., 2013a) although no changes in amygdala
gene expression for selected markers of neuroplasticity or endocrine
function were noted (Nuruddin et al., 2013b).
4.5. Potential mechanisms
The triadic model (Ernst, 2014) provides a framework to describe
how age-dependent changes in motivated behaviors are regulated by
temporal differences in the development and maturation of three neural
systems, namely the prefrontal cortex, amygdala and ventral striatum.
In this model, avoidance behavior is largely influenced by activity in
neural hubs centered on the amygdala that process emotions and are
particularly responsive to aversive stimuli (Ernst, 2014). Approach
behavior is largely regulated by circuits centered on the ventral
striatum, which is also implicated in controlling motivation through the
dopaminergic mesolimbic system (Ernst, 2014). Finally, the activities of
these two systems are coordinated by the prefrontal cortex, with its role
in higher-order information processing and self-control (Ernst, 2014).
The discordance in the development of these three neural systems in
humans is believed to induce increased reward-seeking and risk taking
behaviors from childhood to adolescence, due to early pubertal changes
in the socio-emotional and motivational systems (Ernst, 2014;
Steinberg, 2008). Conversely, the decline in risk-taking that is observed
from adolescence to adulthood results from the later maturation of the
prefrontal top-down driven control system that modulates approach
and avoidance behaviors (Steinberg, 2008). In humans, the mid-ado-
lescence period represents a window of particular vulnerability as the
higher incidence of risk-taking can coincide with behaviors such as
drug and alcohol misuse (Steinberg, 2008). In the present study, GnRHa
and testosterone co-treatment reduced novelty preferences and directed
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decision-making towards more approach and less avoidance suggesting
atypical maturation of the prefrontal cortex is likely.
It is possible that other neural networks may also be affected as a
result of changes in the triadic model as a result of GnRHa and/or
testosterone replacement for example those involved in memory, such
as the amygdala-hippocampal network (Gawda and Szepietowska,
2016). Indeed, verbal cognition is facilitated, in part, through the
amygdala-hippocampus network under regulation of the prefrontal
cortex, as it is involved in initiating, searching and monitoring of
memory. In this regard, it has been shown that people with low anxiety
have better verbal fluency and exhibit increased activation of the right
hemisphere, cerebellum and frontal gyri of the prefrontal cortex, all of
which are thought to improve working memory and information pro-
cessing (Gawda and Szepietowska, 2016). In the present study, voca-
lization rates, as potential indicators of anxiety, were reduced with the
suppression of testosterone signaling. Similarly, vocalization rates
during a spatial task were also reduced (Hough et al., 2017) by sup-
pressing testosterone signaling. This reinforces the hypothesis that the
amygdala-hippocampal network and prefrontal cortex function would
be sensitive to changes in peripubertal testosterone concentrations and
data from this ovine model indicates that peripubertal GnRH and/or
testosterone can have differential effects in these neural regions.
The mechanism(s) through which GnRHa may affect the neural
systems is poorly understood. Results that indicate persisting effects of
elevated GnRH on cognitive function when sex steroids are replaced,
argue against the hypothesis that these effects are secondary to the loss
of sex steroids and this is supported by extensive studies in elderly men
and women (Hogervorst, 2013). Even in such gerontological studies, it
has been suggested that the age-related decline in some types of human
cognition may be influenced by the associated increases in LH and/or
GnRH in the absence of steroid negative feedback (Blair et al., 2015).
Gordon et al. (1986) demonstrated that an acute injection of GnRH in
healthy men (18–35 years of age) improved cognitive performance in a
verbal fluency task, but no effects were observed with testosterone in-
jections, which suggested a GnRH or LH specific effect. This observation
is in line with studies showing that certain cognitive functions will
decline with elevated GnRH, because chronic GnRH-treatment is ex-
pected to have the opposite effect of acute administration (Green et al.,
2000). Using functional magnetic resonance imaging, Craig et al.
(2007) reported that GnRHa-treatment over an 8-week period resulted
in a reduction in verbal encoding (but not retrieval) that was associated
with decreased hemodynamic activation in the left prefrontal cortex,
anterior cingulate and medial frontal gyrus. Similarly, memory loss is a
common side effect in men treated with GnRHa for metastatic prostate
cancer (Flaig and Glode, 2008) and is associated with the decline in
circulating concentrations of both androgens and estrogens (Salminen
et al., 2004; Freedland et al., 2009). However, little is known about the
cognitive effects associated with disrupted GnRH signaling in these
patients.
5. Conclusion
The disruption of both peripubertal GnRH and testosterone sig-
naling interfered with the normal maturational changes expected in
certain aspects of cognitive processes that regulate motivation. There
appears to be a window during late puberty or early adulthood where
suppression of testosterone is associated with lower emotional re-
activity, which will be of relevance for patients receiving GnRHa-
treatment during this time. Increased motivation to approach objects
and preferences for familiarity during young adulthood following
peripubertal GnRHa and exogenous testosterone co-treatment may re-
flect reduced cognitive processes associated with the prefrontal cortex
(e.g. reduced information processing or exaggerated approach as seen
with adolescent risk-taking). The distinct difference between the
GnRHa+T versus the GnRHa and Control groups may have resulted
from loss of endogenous patterns of testosterone secretion, or a
synergistic action between GnRH and testosterone signaling on selected
cognitive processes during the peripubertal period. Imbalance of the
fundamental (across species) motivational tendencies for approach and
avoidance when encountering novel objects or situations may lead to
reduced novelty seeking, and consequently hamper learning and flex-
ible adjustment to environmental change. The findings may be of
clinical relevance where chronic peripubertal GnRHa-treatment is ad-
ministered with or without exogenous sex steroid treatments during this
sensitive window as is the case in central precocious puberty and
gender dysphoria.
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